首页> 外国专利> USE OF A HOLOTOXIN TO REDUCE ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION OF MISFOLDED PROTEINS

USE OF A HOLOTOXIN TO REDUCE ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION OF MISFOLDED PROTEINS

机译:使用全毒素来减少内镜网状结合的错误折叠蛋白质的降解

摘要

Provided is a use of a holotoxin to reduce endoplasmic reticulum-associated degradation (ERAD) of misfolded or abnormally folded proteins The holotoxin can thus be used in a method to treat diseases related to ERAD Examples of misfolded proteins that are degraded in the ER include the cystic fibrosis transmembrane conductance regulator (CFTR) delta F508 mutant protein, a misfolded mutant (G268V) of multi-drug resistance 1 (MDR1), and the glucocerebrosidase (GCC) enzyme in Gaucher' s dis¬ease cells Examples of suitable holotoxins include ricin, shiga toxin, exotoxin A, plasmid-encoded toxin, cholera toxin, and verotoxin 1 (VT1) VT1 is also known as vero-toxin A, shiga-like toxin 1, shiga-like toxin 1, or shiga tox¬in type 1 A non-toxic inactive VT1 can also be used wherein crucial residues of the A subumt active site are mutated, for example, the mutations Y77S and E167Q
机译:提供了全毒素减少错误折叠或异常折叠的蛋白质的内质网相关降解(ERAD)的用途。因此,全毒素可用于治疗与ERAD相关的疾病的方法。在ER中降解的错误折叠蛋白质的例子包括:囊性纤维化跨膜电导调节剂(CFTR)δF508突变蛋白,多重耐药性1(MDR1)的错折叠突变体(G268V)和葡萄糖脑苷脂酶(GCC)酶在高彻病原细胞中的分布合适的全毒素实例包括蓖麻毒素,志贺毒素,外毒素A,质粒编码的毒素,霍乱毒素和维毒素1(VT1)VT1也称为维罗毒素A,志贺样毒素1,志贺样毒素1或志贺毒素1型。也可以使用无毒的无活性VT1,其中突变A亚活性位点的关键残基,例如,突变Y77S和E167Q

著录项

  • 公开/公告号IN2705DEN2012A

    专利类型

  • 公开/公告日2015-09-04

    原文格式PDF

  • 申请/专利权人 THE HOSPITAL FOR SICK CHILDREN;

    申请/专利号IN2012DELNP2705

  • 发明设计人 CLIFFORD LINGWOOD;

    申请日2012-03-28

  • 分类号A61K35/74;A61K38/16;

  • 国家 IN

  • 入库时间 2022-08-21 15:14:18

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号